ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 836

Patient-Reported Outcomes from a Randomised, Open-Label, Parallel-Group Study Evaluating Ixekizumab versus Adalimumab in Patients with PsA Who Are Biologic DMARD Naïve: 24-Week Results

Filip Van den Bosch1, Lars-Erik Kristensen 2, Dennis McGonagle 3, Maurizio Rossini 4, Soyi Liu-Leage 5, Christophe Sapin 5, Gabriella Meszaros 5 and Joseph Merola 6, 1Ghent University Hospital, Ghent, Belgium, 2Copenhagen University Hospital, Bispebjerg-Frederiksberg, Denmark, 3University of Leeds, Leeds, United Kingdom, 4University of Verona, Verona, Italy, 5Eli Lilly and Company, Indianapolis, 6Harvard Medical School, Brigham and Women’s Hospital, Boston, MA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Biologics and patient-reported outcome measures, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S076: Patient Outcomes, Preferences, & Attitudes I: Patient Reported Outcomes (833–838)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Therapeutic options for patients with PsA are increasing but data directly comparing biologics are limited. The multicentre, open-label SPIRIT-H2H trial (NCT03151551) evaluated the efficacy and safety of ixekizumab (IXE) vs adalimumab (ADA) over a 52-week treatment period in biologic DMARD-naïve patients with active PsA. This analysis directly compared the effects of IXE vs ADA on patient-reported outcomes (PROs) and health-related quality of life (HRQoL) after 24 weeks’ treatment in SPIRIT-H2H.

Methods: All patients fulfilled the Classification Criteria for Psoriatic Arthritis (CASPAR). Patients were randomised (1:1) to 52 weeks of IXE (160 mg week 0, then 80 mg every 2 weeks [Q2W] to week 12 and Q4W thereafter for patients with moderate-to-severe plaque psoriasis [PsO] or 160 mg week 0, then 80 mg Q4W for other patients) or ADA (80 mg week 0 then 40 mg Q2W from week 1 for patients with moderate-to-severe PsO or 40 mg week 0 then 40 mg Q2W for other patients). The primary objective was to assess the superiority of IXE vs ADA by comparing the proportion of patients achieving a simultaneous improvement of ≥50% in ACR criteria (ACR50) and 100% in Psoriasis Area Severity Index score (PASI100) at week 24. A number of PROs and HRQoL were evaluated (see Table). PRO changes from baseline to week 24 were analysed using analysis of covariance models with modified baseline observation carried forward imputation. Treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire. Logistic regressions with non-responder imputation in the intent-to-treat population were used to evaluate results.

Results: A total of 566 patients were randomised to IXE or ADA; of these 82% of patients did not have moderate-to-severe PsO. Baseline characteristics were generally balanced between the two treatment groups. The percentage of patients simultaneously achieving ACR50 and PASI100 responses at week 24 was statistically superior for IXE vs ADA (36% vs 28%; p< 0.05). All PRO and HRQoL outcomes (Table) significantly improved from baseline in both treatment groups (p< .001 for all). Treatment with IXE was associated with a statistically significantly greater improvement in itch, Short form-36 Health Survey scores, Role-emotional and Dermatology Life Quality Index (DLQI) scores vs ADA (seen as early as week 4 for itch and DLQI improvement). For patients’ overall satisfaction with treatment, 62.5% of IXE and 59.7% of ADA recipients were mostly satisfied. Both biologics had acceptable safety and tolerability.

Conclusion: In bDMARD-naïve patients with active PsA and PsO, IXE showed superior efficacy compared to ADA based on simultaneous achievement of ACR50 and PASI100 responses at week 24. Both biologics significantly improved HRQoL and other PROs. Greater improvements in PROs related to PsO were observed for IXE- compared to ADA-treated patients.


 


Table. PROs and HRQoL at baseline and least square mean change from baseline at week 24

Table. PROs and HRQoL at baseline and least square mean change from baseline at week 24


Disclosure: F. Van den Bosch, AbbVie, 5, 8, Abbvie, 5, 8, AbbVie, Bristol-Myers Squibb, Celgene, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Sanofi and UCB, 5, 8, ABBVIE, CELGENE, ELI LILLY, GALAPAGOS, MERCK, NOVARTIS, PFIZER, VCB, 5, 8, Bristol-Myers Squibb, 2, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Galapagos, 5, 8, Janssen, 5, 8, Merck, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Sanofi, 5, 8, UCB, 5, 8; L. Kristensen, UCB, 2, 8, Biogen, 2, 8, Janssen pharmaceuticals, 2, 8, Novartis, 2, 8, Pfizer, 8, AbbVie, 8, Amgen, 8, Bristol-Myers Squibb, 8, MSD, 8, Eli Lilly and Company, 8; D. McGonagle, AbbVie, 9, Abbvie, 2, 8, BMS, 9, Celgene, 2, 8, 9, Janssen, 2, 8, Johnson & Johnson, 9, Lilly, 2, 8, MSD, 9, Novartis, 2, 8, 9, Pfizer, 2, 8, 9, UCB, 8, 9; M. Rossini, Abiogen, 5, Biogen, 5, Eli Lilly, 5, 8, Novartis, 5, UCB, 5; S. Liu-Leage, Eli Lilly and Company, 3, 4; C. Sapin, Eli Lilly and Company, 3, 4; G. Meszaros, Eli Lilly and Company, 3, 4; J. Merola, AbbVie, 2, 5, 8, Aclaris, 2, 5, Almirall, 2, 5, Amgen, 5, Biogen, 2, 5, Biogen Idec, 2, 5, Biogen IDEC, 5, Brigham and Women's Hospital, Harvard, 3, Burrage Capital Management Boston Advisory Board, 6, Celgene, 2, 5, Dermavant, 2, 5, Eli Lilly, 2, 5, Eli Lilly and Company, 5, GlaxoSmithKline, 5, GSK, 2, 5, Incyte, 2, 5, Janssen, 2, 5, Leo Pharma, 2, 5, Lilly, 5, Merck, 5, Merck Research Laboratories, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Regeneron, 5, Samumed, 2, 5, Sanofi, 5, Sanofi Regeneron, 2, 5, Science 37, 5, Sun Pharma, 2, 5, UCB, 2, 5.

To cite this abstract in AMA style:

Van den Bosch F, Kristensen L, McGonagle D, Rossini M, Liu-Leage S, Sapin C, Meszaros G, Merola J. Patient-Reported Outcomes from a Randomised, Open-Label, Parallel-Group Study Evaluating Ixekizumab versus Adalimumab in Patients with PsA Who Are Biologic DMARD Naïve: 24-Week Results [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/patient-reported-outcomes-from-a-randomised-open-label-parallel-group-study-evaluating-ixekizumab-versus-adalimumab-in-patients-with-psa-who-are-biologic-dmard-naive-24-week-results/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-reported-outcomes-from-a-randomised-open-label-parallel-group-study-evaluating-ixekizumab-versus-adalimumab-in-patients-with-psa-who-are-biologic-dmard-naive-24-week-results/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology